SPDL1 and renal cell carcinoma: In this study, we quantified sPD-L1 in prospectively collected serum samples from patients in two biomarker-directed clinical trials of PD-1 monotherapy: advanced RCC (CheckMate 009) and melanoma (CheckMate 038 part 1).